0001193125-22-147480.txt : 20220511 0001193125-22-147480.hdr.sgml : 20220511 20220511160133 ACCESSION NUMBER: 0001193125-22-147480 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220511 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220511 DATE AS OF CHANGE: 20220511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ICAD INC CENTRAL INDEX KEY: 0000749660 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 020377419 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09341 FILM NUMBER: 22913594 BUSINESS ADDRESS: STREET 1: 98 SPIT BROOK ROAD, SUITE 100 CITY: NASHUA STATE: NH ZIP: 03062 BUSINESS PHONE: 603-882-5200 MAIL ADDRESS: STREET 1: 98 SPIT BROOK ROAD, SUITE 100 CITY: NASHUA STATE: NH ZIP: 03062 FORMER COMPANY: FORMER CONFORMED NAME: HOWTEK INC DATE OF NAME CHANGE: 19920703 8-K 1 d311484d8k.htm 8-K 8-K
ICAD INC false 0000749660 0000749660 2022-05-11 2022-05-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 11, 2022

 

 

iCAD, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-09341   02-0377419

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

98 Spit Brook Road, Suite 100, Nashua, New Hampshire   03062
(Address of Principal Executive Offices)   (Zip Code)

(603) 882-5200

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.01 par value   ICAD   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition

On May 11, 2022, iCAD, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits

Exhibit 99.1 is being furnished pursuant to Item 2.02, is not to be considered filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference into any of the Company’s previous or future filings under the Securities Act of 1933, as amended, or the Exchange Act.

(d) Exhibits

 

99.1    Press Release of iCAD, Inc. dated May 11, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

iCAD, INC.

(Registrant)

By:  

    /s/ Stacey Stevens

 

    Stacey Stevens

    Chief Executive Officer and President

Date: May 11, 2022

EX-99.1 2 d311484dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

iCAD Reports Financial Results for First Quarter Ended March 31, 2022

Company to host conference call and webcast today at 4:30 PM ET

NASHUA, N.H. – May 11, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2022.

Highlights:

 

•  

Commercial reorganization shows early success leading to a ProFound AI® enterprise agreement at a world-renowned academic research institution with multiple locations throughout the U.S.

 

•  

Profound AI® Risk clinical research progresses, with new data to be presented at both the International Workshop on Breast Imaging (IWBI) and the European Congress of Radiology (ECR) in Q2

 

•  

GLIOX trial examining use of Xoft® intraoperative radiation therapy (IORT) for recurrent glioblastoma (GBM) has accelerated with additional patients treated, and customers globally continue to expand use of Xoft electronic brachytherapy (eBx) for the treatment of multiple tumor types, including rectal, head and neck, and various types of brain cancers

 

•  

Launched a new webinar series, “ProFound Insights, ProFound Impact,” which will highlight compelling customer success stories, such as Kettering Health in Ohio and Wake Radiology in North Carolina

“We are currently at an important inflection point that offers significant potential across both sides of our business,” said Stacey Stevens, President and CEO of iCAD, Inc. “With a robust portfolio of world-leading, differentiated solutions in large, under-penetrated markets in the detection segment, and the expansion of Xoft in promising applications such as the treatment of brain tumors in the cancer therapy segment, iCAD is well positioned for sustained growth.”

“Our results this quarter were achieved through solid execution of our strategic plan, which has laid the groundwork for continued success this year. We will continue to leverage the strength of our robust portfolio of powerful solutions and expand access to our innovative technologies via aggressively targeting broader market opportunities and offering more flexible ways for our technologies to meet customer needs,” continued Stevens.

“We remain optimistic as we look ahead, as we believe we now have a stronger commercial infrastructure in place and a solid and growing pipeline to ensure the trajectory we are on will continue to position the organization for success and bring our leading portfolio of innovative solutions into the hands of more clinicians worldwide. I believe that we have the right plans and the right team in place to successfully execute our strategic vision and elevate the Company and our technologies to new heights,” Stevens added.

First Quarter 2022 Financial Results

Total Detection and Therapy revenue for the first quarter of 2022 was $7.5 million, a decrease of $1.1 million, or 13.0%, as compared to the first quarter of 2022, reflecting an 17.9% decrease in product revenue, and a 4.0% decrease in service and supplies revenue.

In $000’s

 

     Three months ended March 31,  
     2022      2021      $ Change      % Change  

Product revenue

    $ 4,560      $ 5,557      $ (997 )       (17.9 )% 

Service and supplies revenue

      2,963        3,087        (124 )       (4.0 )% 
  

 

 

     

 

 

     

 

 

     

 

 

  

Total Revenue

    $ 7,523      $ 8,644      $ (1,121 )       (13.0 )% 
  

 

 

     

 

 

     

 

 

     

 

 

  

Revenue: Cancer detection revenue for the first quarter of 2022, which includes the Company’s mammography and breast density products, and the associated service and supplies revenue, decreased by approximately $0.2 million, or 3.5%, to $5.5 million, as compared to the first quarter of 2021. Therapy revenue for the first quarter of 2022, which includes Xoft® eBx® System® sales, as well as the associated service and supplies revenue, decreased by $0.9 million, or 31.6%, to $2.0 million, as compared to the first quarter of 2021.

In $000’s

 

     Three months ended March 31,  
     2022      2021      $ Change      % Change  

Detection revenue

            

Product revenue

    $ 3,864      $ 4,161      $ (297 )       (7.1 )% 

Service and supplies revenue

      1,657        1,558        99        6.4 % 
  

 

 

     

 

 

     

 

 

     

 

 

  

Detection Revenue

    $ 5,521      $ 5,719      $ (198 )       (3.5 )% 
  

 

 

     

 

 

     

 

 

     

 

 

  

Therapy revenue

            

Product revenue

    $ 696      $ 1,396      $ (700 )       (50.1 )% 

Service and supplies revenue

      1,306        1,529        (223 )       (14.6 )% 
  

 

 

     

 

 

     

 

 

     

 

 

  

Therapy Revenue

    $ 2,002      $ 2,925      $ (923 )       (31.6 )% 
  

 

 

     

 

 

     

 

 

     

 

 

  

Total Revenue

    $ 7,523      $ 8,644      $ (1,121 )       (13.0 )% 
  

 

 

     

 

 

     

 

 

     

 

 

  

Gross Profit: Gross profit for the first quarter of 2022 was $5.3 million, or 70.6% of revenue, as compared to $6.3 million, or 72.8% of revenue, in the first quarter of 2021.

Operating Expenses: Total operating expenses for the first quarter of 2022 were $8.8 million, a $1.0 million, or 12.9%, increase from $ 7.8 million in the first quarter of 2021.

GAAP Net Loss: Net loss for the first quarter of 2022 was ($3.5) million, or ($0.14) per diluted share, as compared to a net loss of ($1.6) million, or ($0.07) per diluted share, for the first quarter of 2021.

Non-GAAP Adjusted Net Loss: Non-GAAP Adjusted Net Loss, a non-GAAP financial measure as defined below, for the first quarter of 2022 was ($3.5) million, or ($0.14) per diluted share, as compared to a Non-GAAP Adjusted Net Loss of ($1.6) million, or ($0.07) per diluted share, for the first quarter of 2021. Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss results for the three-month periods ended March 31, 2022 and 2021, respectively.

Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA, a non-GAAP financial measure as defined below, for the first quarter of 2022 was a loss of ($2.7) million, a $2.1 million increase as compared to the first quarter 2021 Non-GAAP Adjusted EBITDA loss of ($0.4) million. Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA results for the three-month periods ended March 31, 2022 and 2021, respectively.

Conference Call

Wednesday, May 11 at 4:30 PM ET

Domestic:    888-506-0062
International:    973-528-0011
Conference ID:    728427
Webcast:    https://www.webcaster4.com/Webcast/Page/2879/45416

Use of Non-GAAP Financial Measures

In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company’s operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company’s quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company’s website at www.icadmed.com.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD® is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expected benefits of ProFound AI®, the benefits of the Company’s products, external factors affecting the market for our products, behavior of clients and prospective clients, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Media Inquiries:

Jessica Burns, iCAD

+1-201-423-4492

jburns@icadmed.com

Investor Inquiries:

iCAD Investor Relations

ir@icadmed.com

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands except for share data)

 

     March 31,     December 31,  
     2022     2021  
Assets     

Current assets:

     

Cash and cash equivalents

    $ 29,798     $ 34,282  

Trade accounts receivable, net of allowance for doubtful accounts of $573 in 2022 and $268 in 2021

      10,309       8,891  

Inventory, net

      4,736       4,171  

Prepaid expenses and other current assets

      3,090       2,962  
  

 

 

    

 

 

  

Total current assets

      47,933       50,306  
  

 

 

    

 

 

  

Property and equipment, net of accumulated depreciation of $7,192 in 2022 and $7,106 in 2021

      947       882  

Operating lease assets

      859       1,059  

Other assets

      104       899  

Intangible assets, net of accumulated amortization of $8,776 in 2022 and $8,724 in 2021

      640       683  

Goodwill

      8,362       8,362  
  

 

 

    

 

 

  

Total assets

    $ 58,845     $ 62,191  
  

 

 

    

 

 

  
Liabilities and Stockholders’ Equity     

Current liabilities:

     

Accounts payable

    $ 2,681     $ 2,779  

Accrued and other expenses

      5,128       5,642  

Lease payable - current portion

      887       889  

Deferred revenue

      5,765       5,652  
  

 

 

    

 

 

  

Total current liabilities

      14,461       14,962  
  

 

 

    

 

 

  

Lease payable, long-term portion

      54       266  

Convertible debentures payable to non-related parties, at fair value

      0       —    

Convertible debentures payable to related parties, at fair value

      0       —    

Deferred revenue, long-term portion

      571       441  

Deferred tax

      6       5  
  

 

 

    

 

 

  

Total liabilities

      15,092       15,674  
  

 

 

    

 

 

  

Stockholders’ equity:

     

Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued.

      —         —    

Common stock, $0.01 par value: authorized 60,000,000 shares; issued 25,359,175 as of March 31, 2022 and 25,326,086 as of December 31, 2021.

     

Outstanding 25,173,344 as of March 31, 2022 and 25,140,255 as of December 31, 2021.

      253       253  

Additional paid-in capital

      301,640       300,859  

Accumulated deficit

      (256,725 )      (253,180 ) 

Treasury stock at cost, 185,831 shares in 2022 and 2021

      (1,415 )      (1,415 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

      43,753       46,517  
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 58,845     $ 62,191  
  

 

 

    

 

 

  

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands except for per share data)

 

     Three Months Ended March 31,  
     2022     2021  

Revenue:

     

Products

    $ 4,560     $ 5,557  

Service and supplies

      2,963       3,087  
  

 

 

    

 

 

  

Total revenue

      7,523       8,644  

Cost of revenue:

     

Products

      1,087       1,409  

Service and supplies

      1,049       867  

Amortization and depreciation

      75       79  
  

 

 

    

 

 

  

Total cost of revenue

      2,211       2,355  
  

 

 

    

 

 

  

Gross profit

      5,312       6,289  
  

 

 

    

 

 

  

Operating expenses:

     

Engineering and product development

      2,275       2,192  

Marketing and sales

      3,565       3,424  

General and administrative

      2,931       2,151  

Amortization and depreciation

      63       55  
  

 

 

    

 

 

  

Total operating expenses

      8,834       7,822  
  

 

 

    

 

 

  

Loss from operations

      (3,522 )      (1,533 ) 

Interest expense

      (9 )      (112 ) 

Debt issuance costs

      —         —    

Other income (expense)

      (13 )      2  
  

 

 

    

 

 

  

Other expense, net

      (22 )      (110 ) 

Loss before income tax expense

      (3,544 )      (1,643 ) 
  

 

 

    

 

 

  

Tax expense

      (1 )      —    
  

 

 

    

 

 

  

Net loss and comprehensive loss

    $ (3,545 )    $ (1,643 ) 
  

 

 

    

 

 

  

Net loss per share:

     

Basic

    $ (0.14 )    $ (0.07 ) 
  

 

 

    

 

 

  

Diluted

    $ (0.14 )    $ (0.07 ) 
  

 

 

    

 

 

  

Weighted average number of shares used in computing loss per share:

     

Basic

      25,160       23,929  
  

 

 

    

 

 

  

Diluted

      25,160       23,929  
  

 

 

    

 

 

  

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

    

For the three months ended

March 31,

  
     2022     2021  
              
     (in thousands)  

Cash flow from operating activities:

     

Net loss

    $ (3,545 )    $ (1,643 ) 

Adjustments to reconcile net loss to net cash used for operating activities:

     

Amortization

      53       58  

Depreciation

      86       76  

Bad debt provision

      305       —    

Inventory obsolescence reserve

        —    

Stock-based compensation

      655       935  

Deferred tax

      1       —    

Amortization of debt discount and debt costs

      —         12  

Interest on settlement obligations

        —    

Gain on sale of patent

        —    

Changes in operating assets and liabilities:

     

Accounts receivable

      (1,723 )      (622 ) 

Inventory

      (565 )      647  

Prepaid and other assets

      653       (89 ) 

Accounts payable

      (98 )      (1,617 ) 

Accrued expenses

      (514 )      (1,313 ) 

Deferred revenue

      243       (7 ) 
  

 

 

    

 

 

  

Total adjustments

      (904 )      (1,920 ) 
  

 

 

    

 

 

  

Net cash used for operating activities

      (4,449 )      (3,563 ) 
  

 

 

    

 

 

  

Cash flow from investing activities:

     

Additions to patents, technology and other

      (10 )      —    

Additions to property and equipment

      (151 )      (262 ) 

Acquisition of Radion Inc, and DermEbx

      —         —    

Acquisition of VuComp M-Vu CAD

      —         —    
  

 

 

    

 

 

  

Net cash used for investing activities

      (161 )      (262 ) 
  

 

 

    

 

 

  

Cash flow from financing activities:

     

Proceeds from option exercises pursuant to stock option plans

      66       270  

Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plans

      60       47  

Proceeds from issuance of common stock, net

      —         23,229  

Taxes paid related to restricted stock issuance

      —         —    

Principal payments of capital lease obligations

      —         —    

Issuance of stock upon conversion of debentures

      —         —    

Fair value of convertible debentures

      —         —    

Proceeds from issuance of common stock, net

     
  

 

 

    

 

 

  

Net cash provided by financing activities

      126       23,546  
  

 

 

    

 

 

  

(Decrease) increase in cash and cash equivalents

      (4,484 )      19,721  

Cash and cash equivalents, beginning of period

      34,282       27,186  
  

 

 

    

 

 

  

Cash and cash equivalents, end of period

    $ 29,798     $ 46,907  
  

 

 

    

 

 

  

Supplemental disclosure of cash flow information:

     

Interest paid

    $ 9     $ 92  
  

 

 

    

 

 

  

Taxes paid

    $ —       $ —    
  

 

 

    

 

 

  

Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures

The Company reports its financial results in accordance with United States generally accepted accounting principles, or GAAP. However, management believes that in order to understand the Company’s short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and/or impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company’s ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company’s ongoing business with prior periods more difficult, obscure trends in ongoing operations or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company’s financial and operational performance and comparing this performance to its peers and competitors.

Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP Net Loss before provisions for interest expense, other income, stock-based compensation expense, depreciation and amortization, tax expense, severance, gain on sale of assets, loss on disposal of assets, acquisition and litigation related expenses. Management considers this non-GAAP financial measure to be an indicator of the Company’s operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company’s overall financial performance.

The non-GAAP financial measures do not replace the presentation of the Company’s GAAP financial results and should only be used as a supplement to, not as a substitute for, the Company’s financial results presented in accordance with GAAP. The Company has provided a reconciliation of each non-GAAP financial measure used in its financial reporting and investor presentations to the most directly comparable GAAP financial measure.

Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

 

•  

Interest expense: The Company excludes interest expense which includes interest from debt facility agreements and interest on capital leases from its non-GAAP Adjusted EBITDA calculation.

 

•  

Stock-based compensation expense: excluded as these are non-cash expenses that management does not consider part of ongoing operating results when assessing the performance of the Company’s business, and also because the total amount of expense is partially outside of the Company’s control as it is based on factors such as stock price volatility and interest rates, which may be unrelated to our performance during the period in which the expense is incurred.

 

•  

Amortization and Depreciation: Purchased assets and intangibles are amortized over a period of several years and generally cannot be changed or influenced by management after they are acquired. Accordingly, these non-cash items are not considered by management in making operating decisions, and management believes that such expenses do not have a direct correlation to future business operations. Thus, including such charges does not accurately reflect the performance of the Company’s ongoing operations for the period in which such charges are incurred.

 

•  

Litigation related: These expenses consist primarily of settlement, legal and other professional fees related to litigation. The Company excludes these costs from its non-GAAP measures primarily because the Company believes that these costs have no direct correlation to the core operations of the Company.

On occasion in the future, there may be other items, such as loss on extinguishment of debt, significant asset impairments, restructuring charges or significant gains or losses from contingencies that the Company may exclude if it believes that doing so is consistent with the goal of providing useful information to investors and management.

Non-GAAP Adjusted EBITDA

Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted EBITDA”

(Unaudited)

(In thousands except for per share data)

 

     Three Months Ended March 31,  
     2022     2021  

GAAP Net Loss

    $ (3,545 )    $ (1,643 ) 

Interest Expense

      9       112  

Other (income) expense

      13       (2 ) 

Stock Compensation

      655       935  

Depreciation

      86       76  

Amortization

      53       58  

Tax expense

      1       —    

Litigation related

      —         21  
  

 

 

    

 

 

  

Non-GAAP Adjusted EBITDA

    $ (2,728 )    $ (443 ) 
  

 

 

    

 

 

  
     Three Months Ended March 31,  
     2022     2021  

GAAP Net Loss

    $ (3,545 )    $ (1,643 ) 

Adjustments to Net Loss:

     

Litigation related

      —         21  
  

 

 

    

 

 

  

Non-GAAP Adjusted Net Loss

    $ (3,545 )    $ (1,622 ) 
  

 

 

    

 

 

  

Net Loss per share

     

GAAP Net Loss per share

    $ (0.14 )    $ (0.07 ) 

Adjustments to Net Loss (as detailed above)

      —         —    
  

 

 

    

 

 

  

Non-GAAP Adjusted Net Loss per share

    $ (0.14 )    $ (0.07 ) 
  

 

 

    

 

 

  
 EX-101.SCH 3 icad-20220511.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 icad-20220511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 icad-20220511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 11, 2022
Cover [Abstract]  
Entity Registrant Name ICAD INC
Amendment Flag false
Entity Central Index Key 0000749660
Document Type 8-K
Document Period End Date May 11, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-09341
Entity Tax Identification Number 02-0377419
Entity Address, Address Line One 98 Spit Brook Road
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Nashua
Entity Address, State or Province NH
Entity Address, Postal Zip Code 03062
City Area Code (603)
Local Phone Number 882-5200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value
Trading Symbol ICAD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 d311484d8k_htm.xml IDEA: XBRL DOCUMENT 0000749660 2022-05-11 2022-05-11 ICAD INC false 0000749660 8-K 2022-05-11 DE 001-09341 02-0377419 98 Spit Brook Road Suite 100 Nashua NH 03062 (603) 882-5200 false false false false Common Stock, $0.01 par value ICAD NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d311484d8k.htm d311484dex991.htm icad-20220511.xsd icad-20220511_lab.xml icad-20220511_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d311484d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d311484d8k.htm" ] }, "labelLink": { "local": [ "icad-20220511_lab.xml" ] }, "presentationLink": { "local": [ "icad-20220511_pre.xml" ] }, "schema": { "local": [ "icad-20220511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "icad", "nsuri": "http://www.icad.com/20220511", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d311484d8k.htm", "contextRef": "duration_2022-05-11_to_2022-05-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d311484d8k.htm", "contextRef": "duration_2022-05-11_to_2022-05-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.icad.com//20220511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-22-147480-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-147480-xbrl.zip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